PMID- 17445159
OWN - NLM
STAT- MEDLINE
DCOM- 20070621
LR  - 20081121
IS  - 0001-2815 (Print)
IS  - 0001-2815 (Linking)
VI  - 69 Suppl 1
DP  - 2007 Apr
TI  - Effect of HLA-A2 allele disparity on clinical outcome in hematopoietic cell 
      transplantation from unrelated donors.
PG  - 31-5
AB  - Population-based differences in clinical outcome after unrelated donor 
      hematopoietic cell transplantation suggest that the significance of human 
      leukocyte antigen (HLA) mismatching may be related to locus-specific and 
      allele-specific differences that distinguish ethnically diverse transplant donors 
      and recipients. We studied the risks associated with HLA-A locus mismatching in 
      two large transplant populations from the International Histocompatibility 
      Working Group in hematopoietic cell transplantation data set to better understand 
      permissible and nonpermissible HLA-A mismatches.
FAU - Morishima, Y
AU  - Morishima Y
AD  - Aichi Cancer Center, Nagoya, Japan. ymorisim@aichi-cc.jp
FAU - Kawase, T
AU  - Kawase T
FAU - Malkki, M
AU  - Malkki M
FAU - Petersdorf, E W
AU  - Petersdorf EW
CN  - International Histocompatibility Working Group in Hematopoietic Cell 
      Transplantation Component
LA  - eng
GR  - AI069197/AI/NIAID NIH HHS/United States
GR  - AI33484/AI/NIAID NIH HHS/United States
GR  - AI49213/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (HLA-A2 Antigen)
SB  - IM
MH  - Alleles
MH  - *Blood Donors
MH  - Disease-Free Survival
MH  - Donor Selection
MH  - *Genetic Variation
MH  - Graft Survival
MH  - Graft vs Host Disease/etiology/prevention & control
MH  - HLA-A2 Antigen/*genetics/*immunology
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Histocompatibility
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/*therapy
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2007/04/21 09:00
MHDA- 2007/06/22 09:00
CRDT- 2007/04/21 09:00
PHST- 2007/04/21 09:00 [pubmed]
PHST- 2007/06/22 09:00 [medline]
PHST- 2007/04/21 09:00 [entrez]
AID - TAN759_3 [pii]
AID - 10.1111/j.1399-0039.2006.759_3.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2007 Apr;69 Suppl 1:31-5. doi: 10.1111/j.1399-0039.2006.759_3.x.